(Q44543138)

4 December 2017

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance (English)

1 reference

4 December 2017

0 references

Gordon S Francis

1

1 reference

4 December 2017

Yves Grumser

2

1 reference

4 December 2017

Enrica Alteri

3

1 reference

4 December 2017

Alain Micaleff

4

1 reference

4 December 2017

Fanny O'Brien

5

1 reference

4 December 2017

Jonathan Alsop

6

1 reference

4 December 2017

Margaretha Stam Moraga

7

1 reference

4 December 2017

Neil Kaplowitz

8

1 reference

4 December 2017

1 January 2003

1 reference

4 December 2017

1 reference

4 December 2017

26

1 reference

4 December 2017

11

1 reference

4 December 2017

815-827

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200326110-00006

4 December 2017

0 references

cites work

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Fulminant liver failure during interferon beta treatment of multiple sclerosis

1 reference

12 December 2020

Nefazodone-induced liver failure: report of three cases

1 reference

12 December 2020

Modulation of constitutive and inducible hepatic cytochrome(s) P-450 by interferon beta in mice.

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Drug-induced liver disorders: implications for drug development and regulation

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

1 reference

12 December 2020

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal

1 reference

12 December 2020

Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis

1 reference

12 December 2020

Clinical toxicity of the interferons.

1 reference

12 December 2020

Liver failure due to recombinant alpha interferon

1 reference

12 December 2020

Autoimmune hepatitis and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Depression of drug-metabolizing activity in the human liver by interferon-beta

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00002018-200326110-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

4 December 2017

0 references

1 reference